503 related articles for article (PubMed ID: 19129689)
21. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
[TBL] [Abstract][Full Text] [Related]
22. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
Shander A; Sazama K
Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
[TBL] [Abstract][Full Text] [Related]
23. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
24. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
25. Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload.
Fung EB; Harmatz P; Milet M; Ballas SK; De Castro L; Hagar W; Owen W; Olivieri N; Smith-Whitley K; Darbari D; Wang W; Vichinsky E;
Am J Hematol; 2007 Apr; 82(4):255-65. PubMed ID: 17094096
[TBL] [Abstract][Full Text] [Related]
26. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Kamble RT; Selby GB; Mims M; Kharfan-Dabaja MA; Ozer H; George JN
Biol Blood Marrow Transplant; 2006 May; 12(5):506-10. PubMed ID: 16635785
[TBL] [Abstract][Full Text] [Related]
27. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies.
Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633
[TBL] [Abstract][Full Text] [Related]
28. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
[TBL] [Abstract][Full Text] [Related]
29. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload.
Sivgin S; Baldane S; Akyol G; Keklik M; Kaynar L; Kurnaz F; Pala C; Zararsiz G; Cetin M; Eser B; Unal A
Transfus Apher Sci; 2013 Oct; 49(2):295-301. PubMed ID: 23916904
[TBL] [Abstract][Full Text] [Related]
30. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors.
Majhail NS; DeFor T; Lazarus HM; Burns LJ
Biol Blood Marrow Transplant; 2008 Jul; 14(7):790-4. PubMed ID: 18541198
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of serum hepcidin levels on early infectious complications in allogeneic hematopoietic stem cell transplantation.
Kanda J; Mizumoto C; Kawabata H; Ichinohe T; Tsuchida H; Tomosugi N; Matsuo K; Yamashita K; Kondo T; Ishikawa T; Uchiyama T
Biol Blood Marrow Transplant; 2009 Aug; 15(8):956-62. PubMed ID: 19589485
[TBL] [Abstract][Full Text] [Related]
32. Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen.
Kim DH; Sohn SK; Baek JH; Kim JG; Lee JW; Min WS; Kim DW; Choi SJ; Lee JH; Lee KH; Lee MH; Lee JJ; Kim HJ; Kim CC; Lee KB
Acta Haematol; 2005; 113(4):220-7. PubMed ID: 15983427
[TBL] [Abstract][Full Text] [Related]
33. Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation.
Sivgin S; Baldane S; Kaynar L; Kurnaz F; Pala C; Ozturk A; Cetin M; Unal A; Eser B
Neoplasma; 2012; 59(2):183-90. PubMed ID: 22248276
[TBL] [Abstract][Full Text] [Related]
34. Iron chelation therapy for patients with myelodysplastic syndrome.
Yeh SP; Yang YS; Yao CY; Peng CT
Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
[TBL] [Abstract][Full Text] [Related]
35. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
36. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
[TBL] [Abstract][Full Text] [Related]
37. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.
Malcovati L
Leuk Res; 2007 Dec; 31 Suppl 3():S2-6. PubMed ID: 18037415
[TBL] [Abstract][Full Text] [Related]
38. Iron overload in allogeneic hematopoietic stem cell transplant recipients.
Ali S; Pimentel JD; Munoz J; Shah V; McKinnon R; Divine G; Janakiraman N
Arch Pathol Lab Med; 2012 May; 136(5):532-8. PubMed ID: 22540302
[TBL] [Abstract][Full Text] [Related]
39. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
40. Iron-overload in long-term survivors of hematopoietic transplantation.
Kamble R; Mims M
Bone Marrow Transplant; 2006 Apr; 37(8):805-6. PubMed ID: 16518421
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
